Compare BNZI & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNZI | ALZN |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | 34 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 4.6M |
| IPO Year | N/A | 2021 |
| Metric | BNZI | ALZN |
|---|---|---|
| Price | $3.25 | $1.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $24.00 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 319.0K | 143.2K |
| Earning Date | 05-14-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.28 | N/A |
| Revenue Next Year | $0.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.84 |
| 52 Week High | $8.10 | $3.60 |
| Indicator | BNZI | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 50.68 |
| Support Level | $2.80 | $1.04 |
| Resistance Level | $3.99 | $1.25 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 73.23 | 42.10 |
Banzai International Inc is a Software as a Service (SaaS) company operating in the marketing technology (MarTech) industry. The group provides customers with tools to help them market and sell with greater efficiency and impact. Its customers include Amazon, Dell, Salesforce, Aflac, Thermo Fisher Scientific, RBC Wealth Management, Fitch Group, and many other brands. The Company has three reportable operating segments: Banzai Operating Co, Inc., OpenReel, and Vidello. Its segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions, including video production and editing, for businesses of all sizes. Geographically, it operates in the Americas, Europe, the Middle East and Africa (EMEA), and the Asia Pacific.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.